<DOC>
	<DOCNO>NCT01492426</DOCNO>
	<brief_summary>The purpose study compare effectiveness BMS-790052 ( Daclatasvir ) Telaprevir give combination Peginterferon alfa-2a Ribavirin genotype 1b patient</brief_summary>
	<brief_title>Study Comparing Daclatasvir ( BMS-790052 ) With Telaprevir Combined With Peginterferon Alfa-2a Ribavirin Patients With Chronic Hepatitis C Virus Infection</brief_title>
	<detailed_description>Allocation : Randomized Stratified</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Key Participants chronically infect hepatitis C virus ( HCV ) genotype 1a 1b HCV RNA viral load ≥10,000 IU/mL No prior treatment include limited interferon , ribavirin , directacting antiviral No history cirrhosis liver biopsy within 3 year Fibroscan® within 1 year Body mass index 18 35 kg/m^2 Negative HIV hepatitis B virus Key Evidence decompensated liver disease Evidence medical condition HCV contribute chronic liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Hepatitis C Virus</keyword>
</DOC>